About Paratek Pharma
Paratek Pharma is a Healthcare company based in Boston (United States) founded in 1996, and was acquired by Gurnet Point Capital in June 2023. Therapeutics for antimicrobial resistant infections are developed. Paratek Pharma has raised $96.48 million across 11 funding rounds from investors including Hercules Capital, HHS and Abingworth. The company has 205 employees. Paratek Pharma has completed 2 acquisitions, including OptiNose and Transcept Pharmaceuticals. Its chief executive, as recorded, is Michael Bigham. Paratek Pharma offers products and services including NUZYRA. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Paratek Pharmaceuticals, Inc. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Paratek Pharma was founded in 1996 and is based in Boston, United States. Focus is placed on developing therapeutics to address antimicrobial resistant infections within the pharmaceutical sector. The lead product, NUZYRA (omadacycline), serves as an oral and intravenous antibiotic for treating community-acquired bacterial pneumonia and acute bacterial skin infections in adults. Seysara is also offered for managing inflammatory lesions in moderate to severe acne vulgaris.
- Headquarters Boston, United States
- Employees 205
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website paratekpharma.com
- Social LinkedIn X
- Acquired by Gurnet Point Capital (Jun 2023)
- Legal Name Paratek Pharmaceuticals, Inc.
- Total Equity Funding$96.48M (USD)
in 11 rounds
- InvestorsHercules Capital
& 18 more
- Employee Count205
- Investments & AcquisitionsOptiNose
& 1 more
- Acquired byGurnet Point Capital
(Jun 2023)
Products & Services of Paratek Pharma
Paratek Pharma offers a comprehensive portfolio of products and services, including NUZYRA.
FDA-approved tetracycline-class drug for treating bacterial infections.
Funding Insights of Paratek Pharma
Paratek Pharma has successfully raised a total of $96.48M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $96.48M
- Total Rounds 11
- First Round $36M
(Nov 2002)
- Investors Count 17
Latest 10 of 11 funding rounds of Paratek Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | Grant | – | – | ||
| Apr 2018 | $160M | Post-IPO | – | – | – |
| Jun 2016 | $59.7M | Post-IPO | – | – | – |
| May 2015 | $71.1M | Post-IPO | – | – | – |
| Jul 2014 | $93M | Post-IPO | – | – | – |
| Jun 2014 | $93M | Post-IPO | – | – | |
| Dec 2008 | $3.15M | Grant | – | – | |
| Oct 2007 | $40M | Post-IPO | – | – | |
| Jan 2006 | $25.43M | Series B | – | – | – |
| Jan 2004 | $35.05M | Series B | – | – | – |
19 investors in total: 19 institutional.
Investors in Paratek Pharma
Paratek Pharma has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, HHS and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Venture capital firm | omegafunds.com | Boston, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Venture capital investments are made in innovative healthcare companies. | phase4-partners.com | London, United Kingdom | ||
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
| biovedavc.com | ||||
A center dedicated to supporting biotech innovators in Louisiana. | neworleansbio.com | New Orleans, United States |
Investor details for Paratek Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Paratek Pharma
161 people are tracked at Paratek Pharma (60 in leadership, 4 in board & advisors, 97 in team); the tracked headcount is 205.
| Name | Role | Group |
|---|---|---|
Michael Bigham | CEO | Leadership |
Jared Emerson | Director, Business Insights | Leadership |
Ben Novak | Senior Director Of Government Affairs | Leadership |
Adam Woodrow | President & Chief Commercial Officer | Leadership |
Karen McGrath | Chief People Office | Leadership |
Liron Sissman | Vice President, Business Development | Leadership |
Cathleen F. | Associate Director, Sales Training | Leadership |
Kristen Manion | Vice President Regulatory Affairs Quality And Manufacturing | Leadership |
Patricia R. | Senior Director, Sales Training And Development | Leadership |
Nicole McCann | Regional Business Director, Western Tri-state (pa, Ny, Nj) | Leadership |
David Brown | Regional Business Director- Specialty Sales | Leadership |
Jeanette Straus | Associate Director Field Reimbursement And Patient Services | Leadership |
Alisa Serio | Executive Director, Microbiology And Nonclinical Development | Leadership |
Jody McGuffee | Regional Business Director Bayou Region | Leadership |
Katie Zitoli | Vp, Finance & Controller | Leadership |
Rose Dileo Snyder | Director, Quality Assurance | Leadership |
Diane Anastasiou Mt | Director, Microbiology | Leadership |
Sean Kelly | Regional Business Director Northeast And Mid Atlantic | Leadership |
Jason Boehmer | Executive Director, National Sales | Leadership |
Michele O'Leary | Regional Business Director - Pacific Northwest | Leadership |
141 more people are available in the full profile.
Complete people profiles for Paratek Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Paratek Pharma
Paratek Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OptiNose and Transcept Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of smart devices for nasal drug delivery | optinose.com | Morrisville, United States | 2000 | Mar 2025 | $330M | |
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions | transcept.com | Boston, United States | 1996 | Jul 2014 | •••• |
Complete acquisition details for Paratek Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Paratek Pharma
7 dated milestones of Paratek Pharma across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Paratek Pharma is founded.
- Funding First funding round of $36.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Transcept Pharmaceuticals.
- Funding Latest funding round, Grant,.
- Exit Acquired by Gurnet Point Capital.
- Acquisition Acquires OptiNose.
Competitors of Paratek Pharma
Paratek Pharma has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. |
Detailed competitors of Paratek Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Paratek Pharma
The website of Paratek Pharma (paratekpharma.com) receives about 4K visits a month and ranks #5,533,702 among all websites worldwide, #6,125 in Biotechnology and Pharmaceuticals.
- Monthly visits4K
▲ 33.4% vs previous month
- Unique visitors1.3K
per month
- Global rank#5,533,702
among all websites
- Category rank#6,125
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.7
- Average visit13 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Paratek Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| praxismedicines.com | 100% | 35.6K | #1,244,570 | View details | |
| servier.us | 100% | #2,050,491 | View details | ||
| ensoma.com | 100% | 2.8K | #4,644,561 | View details | |
| pieris.com | 99% | View details | |||
| cellarity.com | 95% | 5.8K | #2,884,812 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Paratek Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Paratek Pharma (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Paratek Pharma
Complete news archive for Paratek Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Paratek Pharma
Paratek Pharma was founded in 1996 and raised its 1st funding round 6 years after it was founded.
Paratek Pharma is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Michael Bigham is the CEO of Paratek Pharma, as recorded in our data.
Paratek Pharma is a funded company, having raised a total of $96.48M across 11 funding rounds to date. The company's 1st funding round was a Series B of $35.05M, raised on Nov 2002.
Paratek Pharma has 205 employees.
Paratek Pharma was founded in 1996 and is based in Boston, United States. Focus is placed on developing therapeutics to address antimicrobial resistant infections within the pharmaceutical sector. The lead product, NUZYRA (omadacycline), serves as an oral and intravenous antibiotic for treating community-acquired bacterial pneumonia and acute bacterial skin infections in adults. Seysara is also offered for managing inflammatory lesions in moderate to severe acne vulgaris.
Paratek Pharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
Paratek Pharma offers NUZYRA.
Paratek Pharma has made 2 acquisitions, including OptiNose, and Transcept Pharmaceuticals.
Paratek Pharma has 19 investors. Key investors include Hercules Capital, HHS, Abingworth, HBM Healthcare Investments, and Lombard Odier.
Paratek Pharma operates through Paratek Pharmaceuticals, Inc..
Yes. Paratek Pharma was acquired by Gurnet Point Capital in June 2023.

